ArticleAdvances in hematology2010
Targeting the hepcidin-ferroportin axis in the diagnosis and treatment of anemias.
Article in Advances in hematology, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 86 citations in OpenAlex.
- Pilot study of the effect of cholecalciferol supplementation on hepcidin in children with chronic kidney disease: Results of the D-fense Trial.Pediatric nephrology (Berlin, Germany) · 2017Trial
- Social defeat stress impairs systemic iron metabolism by activating the hepcidin-ferroportin axis.FASEB bioAdvances · 2024Article
- Targeting iron metabolism in cancer therapy.Theranostics · 2021Review
- Relationship between Selenium and Hematological Markers in Young Adults with Normal Weight or Overweight/Obesity.Antioxidants (Basel, Switzerland) · 2019Article
- Sustained plasma hepcidin suppression and iron elevation by Anticalin-derived hepcidin antagonist in cynomolgus monkey.British journal of pharmacology · 2018Article
- Article
- Vitamin D deficiency and anemia risk in children: a review of emerging evidence.Pediatric health, medicine and therapeutics · 2017Review
- Effects of Testosterone on Erythropoiesis in a Female Mouse Model of Anemia of Inflammation.Endocrinology · 2016Article
- Effects of developmental iron deficiency and post-weaning iron repletion on the levels of iron transporter proteins in rats.Nutrition research and practice · 2015Article
- Hepcidin Mitigates Renal Ischemia-Reperfusion Injury by Modulating Systemic Iron Homeostasis.Journal of the American Society of Nephrology : JASN · 2015Article
- Experience with intravenous ferric carboxymaltose in patients with iron deficiency anemia.Therapeutic advances in hematology · 2014Review
- Vitamin D, race, and risk for anemia in children.The Journal of pediatrics · 2014Article
- Alternatives to blood transfusion.Lancet (London, England) · 2013Review
- Role of hepcidin in the pathophysiology and diagnosis of anemia.Blood research · 2013Article
- Serum hepcidin levels and iron parameters in children with iron deficiency.The Korean journal of hematology · 2012Article
- Hepcidin in anemia of chronic kidney disease: review for the pediatric nephrologist.Pediatric nephrology (Berlin, Germany) · 2012Review
- Timing and determinants of erythropoietin deficiency in chronic kidney disease.Clinical journal of the American Society of Nephrology : CJASN · 2012Article
- Anemia in children with chronic kidney disease.Nature reviews. Nephrology · 2011Review
- Rescuing iron-overloaded macrophages by conservative relocation of the accumulated metal.British journal of pharmacology · 2011Article
- Urinary hepcidin level as an early predictor of iron deficiency in children: A case control study.Italian journal of pediatrics · 2011Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
Abstract
The hepatic peptide hormone hepcidin regulates dietary iron absorption, plasma iron concentrations, and tissue iron distribution. Hepcidin acts by causing the degradation of its receptor, the cellular iron exporter ferroportin. The loss of ferroportin decreases iron flow into plasma from absorptive enterocytes, from macrophages that recycle the iron of senescent erythrocytes, and from hepatocytes that store iron, thereby lowering plasma iron concentrations. Malfunctions of the hepcidin-ferroportin axis contribute to the pathogenesis of different anemias. Deficient production of hepcidin causes systemic iron overload in iron-loading anemias such as beta-thalassemia; whereas hepcidin excess contributes to the development of anemia in inflammatory disorders and chronic kidney disease, and may cause erythropoietin resistance. The diagnosis of different forms of anemia will be facilitated by improved hepcidin assays, and the treatment will be enhanced by the development of hepcidin agonists and antagonists.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.